SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Tatva Chintan Pharma - Quaterly Results

25 Jul 2022 Evaluate
The sales declined to Rs. 860.65 millions for the June 2022 quarter as compared to Rs. 1076.50 millions during the corresponding quarter last year.Net Profit of the company move down -64.52% to Rs. 85.00  millions from Rs. 239.56 millions  in the same quarter last year.A decline of 153.26 millions was observed in the OP in the quarter ended June 2022 from 283.16 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 860.65 1076.50 -20.05 860.65 1076.50 -20.05 4278.11 2911.88 46.92
Other Income 18.29 15.69 16.57 18.29 15.69 16.57 105.06 50.98 106.08
PBIDT 153.26 283.16 -45.88 153.26 283.16 -45.88 1162.77 702.85 65.44
Interest 10.17 14.39 -29.33 10.17 14.39 -29.33 48.32 42.07 14.86
PBDT 143.09 268.77 -46.76 143.09 268.77 -46.76 1114.45 660.78 68.66
Depreciation 23.33 18.98 22.92 23.33 18.98 22.92 81.80 67.30 21.55
PBT 119.76 249.79 -52.06 119.76 249.79 -52.06 1032.65 593.48 74.00
TAX 34.76 10.23 239.78 34.76 10.23 239.78 72.79 79.89 -8.89
Deferred Tax 3.73 -31.47 -111.85 3.73 -31.47 -111.85 -107.29 -23.77 351.37
PAT 85.00 239.56 -64.52 85.00 239.56 -64.52 959.86 513.59 86.89
Equity 221.65 200.88 10.34 221.65 200.88 10.34 221.65 200.88 10.34
PBIDTM(%) 17.81 26.30 -32.30 17.81 26.30 -32.30 27.18 24.14 12.60

Tatva Chintan Pharma Share Price

1275.10 -8.55 (-0.67%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
BASF India 3703.10
Tata Chemicals 709.05
SRF 2493.65
Pidilite Inds. 1393.25
Deepak Nitrite 1538.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×